eBAT is designed to simultaneously target EGFR on solid tumors and uPAR on the vascular and inflammatory tumor microenvironment, thereby targeting cancer cells, as well as the cells that comprise the cancer niche to deliver a catalytic toxin, while minimizing effects on normal tissues [2,3]. The gene discussed is EGFR; the disease is cancer.